Radiancy Inc announced that the U.S. Food and Drug Administration (FDA) has granted it clearance to market the company's new SPR Clinical Phototherapy System for the treatment of pigmented and vascular lesions.

The new SPR system is the latest advance from Radiancy, featuring the company's proprietary LHE (light heat energy) technology, where light and heat energy are combined to achieve a variety of therapeutic and aesthetic effects, with no patient downtime and virtually no side effects.

Internationally, the LHE technology already holds a leadership position with physicians in the effective treatment of numerous skin conditions, including pigmented and vascular lesions, acne vulgaris, hair removal and psoriasis.

"The FDA clearance of the SPR positions the system for dynamic growth in the US," stated Fabian Tenenbaum, Vice President of Marketing and Sales for Radiancy. "For a relatively low investment, physicians can now enhance their aesthetic practice by providing a new safe and effective phototherapy modality to treat the effects of aging and sun damaged skin."